Please assess the completion status of the following clinical trial:

Trial Title: Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: ECT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have required at least 4 transfusions in the past 12 months~* PNH type III red blood cell (RBC) clone by flow cytometry of \>10%~* Lactate dehydrogenase (LDH) level \> 1.5 x upper limit of normal~* Platelet count \> 100,000/mm3~* Patient taking erythropoietin must be on a stable dose for at least 26 weeks~* Patient taking immunosuppressants must be on a stable dose for at least 26 weeks~* Patient taking corticosteroids must be on a stable dose for at least 4 weeks~* Patient taking coumadin must be at a stable INR for at least 4 weeks~* Patient taking iron supplements or folic acid must be on a stable dose for 4 weeks~* Willing and able to give written informed consent~* Must avoid conception~Exclusion Criteria:~* Mean hemoglobin level prior to transfusion over the previous 12 months is \>10.5 gm/dl~* Absolute neutrophil count \<500/ul~* Active bacterial infection~* Hereditary complement deficiency~* Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures within 30 days~* Pregnant, breast-feeding, or intending to conceive~* History of meningococcal disease~* History of bone marrow transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).